Clinical trial · Observational
Observation Study: Superselective Drug-Eluting Chemoembolization in Unresectable Intermediate and Advanced HCC Patients
Superselective Drug-Eluting Chemoembolization in Unresectable Intermediate and Advanced HCC Patients: Safety & Efficacy Registry in Taiwan (SUPER- Taiwan)
NCT03273608CI-TRIAL-00029431unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this multicenter registry is to gather the safety, efficacy and survival data in intermediate and advanced HCC patients treated drug-eluting microsphere in Taiwan in order to provide clinical evidence in HCC management to physicians in the region, and to support the application of deTACE in treating advanced HCC patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- 1 year
- description
- To define all participants from the day of the first HepaSphere Treatment until end of study or death is reported, whichever comes first.
Secondary outcomes (2)
- measure
- Tumor Response
- timeFrame
- 1 year
- description
- Tumor response will be assessed using modified Response Evaluation Criteria In Solid Tumors (mRECIST) criteria to evaluate tumor necrosis under CT/ MRI and will be presented as %.
- measure
- Adverse Event (AE)
- timeFrame
- 1 year
- description
- Adverse event will be accessed according to CTCAE 4.0 after treatments until end of study or death.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria:Patients must meet all of the following inclusion criteria in order to be entered into the study: * Age 20 or older. * Patient has signed informed consent. * Patient must have a diagnosis of hepatocellular cancer confirmed by AASLD and at least one of the following method: * Magnetic resonance imaging (MRI) with early enhancement and delayed enhancement washout of at least one solid liver lesion \> 1 cm. * Contrast enhanced computed tomography (CT) with early enhancement and delayed enhancement washout of at least one solid liver lesion \> 1 cm. * Histological confirmation is required for lesions with inconclusive features. * Patient must not be suitable for treatment by resection or percutaneous ablation at time of study entry. * Patients not suitable for ablation due to lesion location may be enrolled. * Patients with HCC recurrence but not suitable for resection or ablation maybe enrolled. * Patient MUST be with either BCLC stage B OR C, and meet the following criteria: * Stage Child-Pugh A or B AND * Performance status ECOG ≤ 1 WITH Vascular Invasion or WITHOUT Vascular invasion. * Patient has a life expectancy of at least 6 months. Exclusion Criteria:If patients meet any of the following criteria they may not be entered into the study: * Current or previous treatment with chemo- or radiation therapy or sorafenib or drug-eluting chemoembolization (deTACE). * Patients with concurrent cancer except non-melanomatous skin cancer. * Female patients who are pregnant, breastfeeding, or premenopausal and not using an effective method of contraceptive. * Performance status ECOG \> 1. * Child-Pugh Class C. * Occlusive tumor thrombus to the main portal trunk. * Active gastrointestinal bleeding. * Evidence of uncorrectable bleeding diathesis. * Extra-Hepatic spread of the HCC. * Encephalopathy not adequately controlled medically. * Presence of ascites not controlled medically. * Any contraindication for MRI/ CT (eg. metallic implants). * Allergy to contrast media that cannot be managed with prophylaxis. * Any contraindication to arteriography. * Any contraindication for doxorubicin administration. * Any contraindication for hepatic embolization. Porto-systemic shunt, or an arteriovenous shunt that cannot be adequately closed prior to chemoembolization. Hepatofugal blood flow. Serum creatinine \> 2mg/dL. Other condition deemed exclusionary by physician. Uncorrectable impaired clotting.
References
Publications (0)
Data not yet available
No reference posted for this study.